Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Si Lian kang after colonoscopy trial
ChiCTR1900021736Phase 4Completed
- Sponsor
- The First Medical Center of Chinese PLA General Hospital
- Start
- Mar 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of Bifidobacterium tetravaccine in Gastrointestinal microbiome disorder (GMD) (2 arms), sponsored by The First Medical Center of Chinese PLA General Hospital. Primary endpoint: Incidence of diarrhea within 14 days. Started Mar 2019; status: completed.
02
Drugs
Bifidobacterium tetravaccine
03
Conditions
Gastrointestinal microbiome disorder (GMD)
Beyond the preview
Go deeper on ChiCTR1900021736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021736.